ArticleJournal of biomedicine & biotechnology2007
The many facets of SDF-1alpha, CXCR4 agonists and antagonists on hematopoietic progenitor cells.
Article in Journal of biomedicine & biotechnology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 45 citations in OpenAlex.
- Preclinical evaluation of CXCR4 peptides for targeted radionuclide therapy in glioblastoma.EJNMMI radiopharmacy and chemistry · 2024Article
- Chemokines as possible therapeutic targets in metastatic melanoma.Cancer medicine · 2023Review
- Vascular endothelial growth factor-C in activating vascular endothelial growth factor receptor-3 and chemokine receptor-4 in melanoma adhesion.Journal of cellular and molecular medicine · 2022Review
- Closer to Nature: The Role of MSCs in Recreating the Microenvironment of the Hematopoietic Stem Cell Niche in vitro.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2022Review
- At the Bench: Pre-clinical evidence for multiple functions of CXCR4 in cancer.Journal of leukocyte biology · 2021Review
- Precision Medicine Gains Momentum: Novel 3D Models and Stem Cell-Based Approaches in Head and Neck Cancer.Frontiers in cell and developmental biology · 2021Review
- Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.PloS one · 2017Article
- Quantifying adhesion mechanisms and dynamics of human hematopoietic stem and progenitor cells.Scientific reports · 2015Article
- Differential expression and prognostic value of the chemokine receptor CXCR4 in bronchopulmonary neuroendocrine neoplasms.Oncotarget · 2015Article
- Article
- Interaction of a CD44+ head and neck squamous cell carcinoma cell line with a stromal cell-derived factor-1-expressing supportive niche: AnOncology letters · 2014Article
- Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.Current topics in medicinal chemistry · 2014Review
- SDF-1-CXCR4 differentially regulates autoimmune diabetogenic T cell adhesion through ROBO1-SLIT2 interactions in mice.Diabetologia · 2013Article
- Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells.Proceedings of the National Academy of Sciences of the United States of America · 2010Article
- Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.Seminars in cancer biology · 2009Review
- Inhibition of CXCR4 by CTCE-9908 inhibits breast cancer metastasis to lung and bone.Oncology reports · 2009Article
- Molecular cloning, characterization, and expression analysis of the CXCR4 gene from Turbot: Scophthalmus maximus.Journal of biomedicine & biotechnology · 2009Article
- Innovative method for quantification of cell-cell adhesion in 96-well plates.Cell adhesion & migrationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stromal cell-derived factor-1alpha (SDF-1alpha) has pleiotropic effects on hematopoietic progenitor cells (HPCs). We have monitored podia formation, migration, proliferation, and cell-cell adhesion of human HPC under the influence of SDF-1alpha, a peptide agonist of CXCR4 (CTCE-0214), a peptide antagonist (CTCE-9908), and a nonpeptide antagonist (AMD3100). Whereas SDF-1alpha induced migration of CD34(+) cells in a dose-dependent manner, CTCE-0214, CTCE-9908, and AMD3100 did not induce chemotaxis in this concentration range albeit the peptides CTCE-0214 and CTCE-9908 increased podia formation. Cell-cell adhesion of HPC to human mesenchymal stromal cells was impaired by the addition of SDF-1alpha, CTCE-0214, and AMD3100. Proliferation was not affected by SDF-1alpha or its analogs. Surface antigen detection of CXCR4 was reduced upon treatment with SDF-1alpha or AMD3100 and it was enhanced by CTCE-9908. Despite the fact that all these molecules target the same CXCR4 receptor, CXCR4 agonists and antagonists have selective effects on different functions of the natural molecule.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.